No Data
No Data
Oppenheimer Maintains ESSA Pharma(EPIX.US) With Buy Rating, Maintains Target Price $17
Oppenheimer analyst Leland Gershell maintains $ESSA Pharma(EPIX.US)$ with a buy rating, and maintains the target price at $17.According to TipRanks data, the analyst has a success rate of 36.7% and
Oppenheimer Sticks to Their Buy Rating for ESSA Pharma (EPIX)
Prior Reported, ESSA Pharma Presents Data on Prostate Cancer Therapy Masofaniten at ESMO 2024, Shows Prolonged PSA Reduction
ESSA Pharma (NASDAQ:EPIX) Is In A Good Position To Deliver On Growth Plans
ESSA Pharma Inc. (EPIX): Wall Street Analysts Recommend This Canadian Stock Right Now
Express News | ESSA Pharma - Combination of Masofaniten Plus Enzalutamide Continues to Be Well Tolerated With Durable Reductions in Psa in Patients With Mcrpc